Monoamine oxidase a inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: An [11C]-harmine PET study

Journal of Psychiatry and Neuroscience

Volumn 36, Issue 6, 2011, Pages 375-382

  Sacher, Julia ^a,b,c   Houle, Sylvain ^a   Parkes, Jun ^a   Rusjan, Pablo ^a   Sagrati, Sandra ^a,b   Wilson, Alan A ^a   Meyer, Jeffrey H ^a,b  

^a Vivian M Rakoff PET Imaging Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; HARMINE C 11; HYPERICUM PERFORATUM EXTRACT; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; TRACER; UNCLASSIFIED DRUG;

ADULT; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; ENZYME BINDING; ENZYME INHIBITION; FEMALE; HIPPOCAMPUS; HUMAN; HYPERICUM PERFORATUM; MAJOR DEPRESSION; MALE; MESENCEPHALON; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PUTAMEN; RECEPTOR OCCUPANCY; STEADY STATE; TEMPORAL CORTEX; THALAMUS;

EID: 80054828292     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.100117     Document Type: Article

References (52)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
2. Ustün TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-92.
3. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as secondstep treatments: a STAR*D report. Am J Psychiatry 2007;164:739-52.
4. Blier P. The well of novel antidepressants: running dry. J Psychiatry Neurosci 2010;35:219-20.
5. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006;7:295-309.
6. Kent JM, Coplan JD, Lombardo I, et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. Psychopharmacology (Berl) 2002;164:341-8.
7. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35.
8. Tauscher J, Jones C, Remington G, et al. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002; 7: 317-21.
9. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001; 158: 1843-9.
10. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic anti - depressant administration. Neuropsychopharmacology 2003;28: 413-20.
11. Learned-Coughlin SM, Bergstrom M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as meas - ured by positron emission tomography. Biol Psychiatry 2003;54:800-5.
12. Meyer JH, Goulding VS, Wilson AA, et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002;163:102-5.
13. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006; 63: 1209-16.
14. Barton DA, Esler MD, Dawood T, et al. Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry 2008;65:38-46.
15. Meyer JH, Wilson AA, Sagrati S, et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery and recurrence. Arch Gen Psychiatry 2009;66:1304-12.
16. Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 1996;93: 14065-9.
17. Vorbach EU, Hubner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imip - ramine: randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S19-23.
18. Linde K. St. John's wort - an overview. Forsch Komplementmed 2009; 16:146-55.
19. Rosack J. Controversy erupts over study of St. John's Wort efficacy. Psychiatr News 2002;37:26-48.
20. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997;30(Suppl 2): 108-12.
21. Suzuki O, Katsumata Y, Oya M, et al. Inhibition of monoamine oxidase by hypericin. Planta Med 1984;50:272-4.
22. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York (NY): Biometrics Research, New York State Psychiatric Institute; 2002.
23. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington (DC): American Psychiatric Press, Inc.; 1997.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
25. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol 1979; 47: 343-52.
26. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003;9:97-140.
27. Biber A, Fischer H, Romer A, et al. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998;31(Suppl 1):36-43.
28. Schulz HU, Schurer M, Bassler D, et al. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Arzneimittelforschung 2005; 55: 561-8.
29. 11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab 2006; 26: 330-44.
30. Sacher J, Wilson AA, Houle S, et al. Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry 2010;67:468-74.
31. Studholme C, Hill D, Hawkes D. An overlap invariant entropy measure of 3D medical image alignment. Pattern Recognit 1999; 32: 71-86.
32. Ashburner J, Neelin P, Collins DL, et al. Incorporating prior knowledge into image registration. Neuroimage 1997;6:344-52.
33. Rusjan P, Mamo D, Ginovart N, et al. An automated method for the extraction of regional data from PET images. Psychiatry Res 2006; 147:79-89.
34. Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007;10:1116-24.
35. Bottlaender M, Dolle F, Guenther I, et al. Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone. J Pharmacol Exp Ther 2003;305:467-73.
36. Korde A, Sudha G, Smith H, et al. Radiochemical synthesis, automation, and in vivo biodistribution of 4-[18F] Fluorobenzyl- Harmine (F-18 FB-Harmine). J Nucl Med 2010;51(Suppl 2):298.
37. Tweedie DJ, Burke MD. Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitoneor 3-methylcholanthrene-treated mice. Identification and quantitation of two novel harmine metabolites. Drug Metab Dispos 1987; 15: 74-81.
38. Cunningham VJ, Rabiner EA, Slifstein M, et al. Measuring drug occupancy in the absence of a reference region: the Lassen plot revisited. J Cereb Blood Flow Metab 2010;30:46-50.
39. Da Prada M, Kettler R, Keller HH, et al. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of mono - amine oxidase type A. J Pharmacol Exp Ther 1989;248:400-14.
40. Müller WE, Rolli M, Schafer C, et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;30(Suppl 2):102-7.
41. Argyelán M, Szabo Z, Kanyo B, et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 2005;89:115-23.
42. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-58.
43. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-50.
44. Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 2006;185:395-9.
45. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25:871-80.
46. Botte L, Gilles C, Evrard JL, et al. Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium. Acta Psychiatr Scand Suppl 1990;360:42.
47. Casacchia M, Carolei A, Barba C, et al. A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiatry 1984;17:122-5.
48. Versiani M, Oggero U, Alterwain P, et al. A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry Suppl 1989;(6):72-7.
49. Blier P. Resiliency of monoaminergic systems: the 80% rule and its relevance to drug development. J Psychopharmacol 2008;22:587-9.
50. Saura J, Kettler R, Da Prada M, et al. Quantitative enzyme radio - autography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peri - pheral organs, and human brain. J Neurosci 1992;12:1977-99.
51. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984;104:277-86.
52. Rabiner EA, Bhagwagar Z, Gunn RN, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 2001;158:2080-2.